CBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Crescent Biopharma Inc (CBIO) is not a good buy for a beginner, long-term investor at this time. The stock lacks strong positive catalysts, has weak financial performance, and shows bearish technical indicators. While analysts have high long-term price targets, the company is in the early stages of development with no immediate growth drivers or revenue generation. The lack of trading signals and neutral sentiment from hedge funds and insiders further support a hold recommendation.
The stock shows bearish technical indicators. The MACD is below 0 and negatively contracting, the RSI is neutral at 21.43, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 9.815, with support at 8.864 and resistance at 10.767.
and positive outlooks for the company's lead asset CR-001 and its proprietary ADC pipeline. The company is positioned at the forefront of oncology development.
EPS dropped significantly (-90.22% YoY). There is no recent news or congress trading data, and hedge funds and insiders show neutral sentiment. Technical indicators are bearish, and the stock has a low probability of short-term gains.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$24.6M, which improved by 150.47% YoY. EPS dropped significantly to -1.49 (-90.22% YoY). The company has no gross margin.
Analysts from Piper Sandler and Guggenheim have initiated coverage with Buy/Overweight ratings and a $35 price target. They highlight the potential of the company's lead asset CR-001 and its ADC pipeline, but these are long-term prospects with no immediate impact on the stock price.
